

# Mario C Raviglione

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6860368/publications.pdf>

Version: 2024-02-01

237  
papers

29,306  
citations

5268

83  
h-index

5120

166  
g-index

242  
all docs

242  
docs citations

242  
times ranked

20423  
citing authors

#	ARTICLE	IF	CITATIONS
1	Political rationale, aims, and outcomes of health-related high-level meetings and special sessions at the UN General Assembly: A policy research observational study. PLoS Medicine, 2022, 19, e1003873.	8.4	8
2	Waiting for the truth: is reluctance in accepting an early origin hypothesis for SARS-CoV-2 delaying our understanding of viral emergence?. BMJ Global Health, 2022, 7, e008386.	4.7	10
3	A Multisectoral Approach to Tuberculosis Control and Elimination in the Era of the United Nations Sustainable Development Goals. , 2021, , 349-358.		0
4	Tuberculosis: WHO-Recommended Strategies and Global Health Perspectives. , 2021, , 37-45.		0
5	Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019. Emerging Infectious Diseases, 2021, 27, 648-650.	4.3	64
6	Tuberculosis in the Western Pacific Region: Estimating the burden of disease and return on investment 2020-2030 in four countries. The Lancet Regional Health - Western Pacific, 2021, 11, 100147.	2.9	5
7	Synergy between government and non-governmental organizations in health: WHO and the Union collaboration in tuberculosis control. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 24, 100251.	1.3	1
8	Basic and Descriptive Epidemiology of Tuberculosis. , 2021, , 29-36.		0
9	Impact of socio-economic factors on Tuberculosis treatment outcomes in north-eastern Uganda: a mixed methods study. BMC Public Health, 2021, 21, 2167.	2.9	22
10	Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. Journal of Clinical Medicine, 2020, 9, 101.	2.4	16
11	Build back stronger universal health coverage systems after the COVID-19 pandemic: the need for better governance and linkage with universal social protection. BMJ Global Health, 2020, 5, e004020.	4.7	32
12	Harnessing the energy of the corporate sector to end TB: BE health. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100206.	1.3	0
13	A postgraduate qualification in tuberculosis-Message in a bottle. International Journal of Infectious Diseases, 2020, 92, S100-S102.	3.3	1
14	TB Elimination Requires Discovery and Development of Transformational Agents. Applied Sciences (Switzerland), 2020, 10, 2605.	2.5	6
15	Celebrating World Tuberculosis Day at the time of COVID-19. European Respiratory Journal, 2020, 55, 2000650.	6.7	41
16	Use of Digital Technology to Enhance Tuberculosis Control: Scoping Review. Journal of Medical Internet Research, 2020, 22, e15727.	4.3	41
17	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. European Respiratory Review, 2019, 28, 190035.	7.1	107
18	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257

#	ARTICLE	IF	CITATIONS
19	No accountability, no results—the difficult task of advocating for tuberculosis solutions. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 353-354.	9.1	1
20	Trends in tuberculosis in the UK. <i>Thorax</i> , 2018, 73, 702-703.	5.6	24
21	A roadmap for zoonotic tuberculosis: a One Health approach to ending tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 137-138.	9.1	22
22	The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 299-314.	10.7	311
23	The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1. <i>The Lancet Global Health</i> , 2018, 6, e514-e522.	6.3	110
24	Tuberculosis research and development: seeding the future. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 242-244.	10.7	13
25	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 675-683.	9.1	119
26	The World Health Organization standards for tuberculosis care and management. <i>European Respiratory Journal</i> , 2018, 51, 1800098.	6.7	57
27	Tuberculosis makes it onto the international political agenda for health—finally. <i>The Lancet Global Health</i> , 2018, 6, e20-e21.	6.3	17
28	Global Epidemiology of Tuberculosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 271-285.	2.1	250
29	Ending tuberculosis in India: A political challenge & an opportunity. <i>Indian Journal of Medical Research</i> , 2018, 147, 217.	1.0	10
30	Target regimen profiles for treatment of tuberculosis: a WHO document. <i>European Respiratory Journal</i> , 2017, 49, 1602352.	6.7	25
31	Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action. <i>European Respiratory Journal</i> , 2017, 50, 1700946.	6.7	9
32	Ending infectious diseases in the era of the Sustainable Development Goals. <i>Porto Biomedical Journal</i> , 2017, 2, 140-142.	1.0	19
33	Aiming for zero tuberculosis transmission in low-burden countries. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 846-848.	10.7	13
34	Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives. <i>European Respiratory Journal</i> , 2017, 50, 1701632.	6.7	12
35	Tuberculosis control, and the where and why of artificial intelligence. <i>ERJ Open Research</i> , 2017, 3, 00056-2017.	2.6	22
36	Zoonotic tuberculosis in human beings caused by <i>Mycobacterium bovis</i> —a call for action. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e21-e25.	9.1	265

#	ARTICLE	IF	CITATIONS
37	Harnessing the Power of Data to Guide Local Action and End Tuberculosis. <i>Journal of Infectious Diseases</i> , 2017, 216, S669-S672.	4.0	7
38	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701414.	6.7	21
39	Tuberculosis, <i>Public Health Aspects.</i> , 2017, , 252-266.		1
40	Tuberculosis <i>Epidemiology.</i> , 2017, , 229-240.		0
41	Migrant health and tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 599-600.	1.2	3
42	Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions. <i>PLoS Medicine</i> , 2016, 13, e1001965.	8.4	50
43	Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. <i>Gastroenterology Insights</i> , 2016, 8, 6570.	1.2	175
44	Population-based resistance of <i>Mycobacterium tuberculosis</i> isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1185-1192.	9.1	151
45	Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice. <i>European Respiratory Journal</i> , 2016, 48, 1571-1581.	6.7	35
46	Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. <i>New England Journal of Medicine</i> , 2016, 375, 1081-1089.	27.0	109
47	Engaging health-care workers to reduce tuberculosis transmission. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 883-885.	9.1	6
48	Tuberculosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16076.	30.5	830
49	The Internet of Things to come: digital technologies and the End TB Strategy. <i>BMJ Global Health</i> , 2016, 1, e000038.	4.7	6
50	Digital health for the End TB Strategy: developing priority products and making them work. <i>European Respiratory Journal</i> , 2016, 48, 29-45.	6.7	61
51	TB deaths rank alongside HIV deaths as top infectious killer. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 143-144.	1.2	12
52	The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 148-150.	1.8	132
53	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. <i>European Respiratory Journal</i> , 2016, 47, 686-688.	6.7	17
54	Latent <i>Mycobacterium tuberculosis</i> Infection. <i>New England Journal of Medicine</i> , 2015, 372, 2127-2135.	27.0	578

#	ARTICLE	IF	CITATIONS
55	WHO's End TB Strategy: From stopping to ending the global TB epidemic. Indian Journal of Tuberculosis, 2015, 62, 196-199.	0.7	37
56	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1838-1839.	6.7	9
57	Multidrug-resistant tuberculosis around the world: what progress has been made?. European Respiratory Journal, 2015, 45, 150-160.	6.7	104
58	Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Annals of Internal Medicine, 2015, 163, 52-58.	3.9	51
59	WHO's new End TB Strategy. Lancet, The, 2015, 385, 1799-1801.	13.7	834
60	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
61	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
62	The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation. European Respiratory Journal, 2015, 46, 307-311.	6.7	20
63	Latent <i>Mycobacterium tuberculosis</i> Infection. New England Journal of Medicine, 2015, 373, 1178-1180.	27.0	48
64	Global Epidemiology of Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017798-a017798.	6.2	163
65	TUBERCULOSIS: EPIDEMIOLOGY AND CONTROL. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014070.	1.3	116
66	Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. European Respiratory Journal, 2014, 44, 1412-1417.	6.7	32
67	Beyond UHC: Monitoring Health and Social Protection Coverage in the Context of Tuberculosis Care and Prevention. PLoS Medicine, 2014, 11, e1001693.	8.4	110
68	Toward Tuberculosis Elimination in Low-Incidence Countries: Reflections From a Global Consultation. Annals of Internal Medicine, 2014, 161, 670.	3.9	9
69	Quality Tuberculosis Care. All Should Adopt the New International Standards for Tuberculosis Care. Annals of the American Thoracic Society, 2014, 11, 397-398.	3.2	4
70	Rapid impact of effective chemotherapy on transmission of drug-resistant tuberculosis: pity the guinea pig. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1009-1011.	1.2	2
71	Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. European Respiratory Journal, 2014, 43, 1763-1775.	6.7	423
72	Tuberculosis elimination: dream or reality? The case of Cyprus. European Respiratory Journal, 2014, 44, 543-546.	6.7	46

#	ARTICLE	IF	CITATIONS
73	Rebalancing the global battle against tuberculosis. <i>The Lancet Global Health</i> , 2014, 2, e71-e72.	6.3	6
74	World TB Day 2014: finding the missing 3 million. <i>Lancet, The</i> , 2014, 383, 1016-1018.	13.7	44
75	Tuberculosis control: hard questions. <i>Lancet, The</i> , 2014, 384, 1744.	13.7	3
76	Tuberculosis elimination: theory and practice in Europe. <i>European Respiratory Journal</i> , 2014, 43, 1410-1420.	6.7	148
77	Moving the goalposts for tuberculosis targets in Africa. <i>Lancet, The</i> , 2013, 382, 27.	13.7	2
78	Household tuberculosis interventions—how confident are we?. <i>Lancet, The</i> , 2013, 382, 1157-1159.	13.7	1
79	Tuberculosis, <i>Epidemiology of.</i> , 2013, , 353-380.		0
80	Perspective: Weigh all TB risks. <i>Nature</i> , 2013, 502, S13-S13.	27.8	10
81	WHO and the future of disease control programmes. <i>Lancet, The</i> , 2013, 381, 413-418.	13.7	43
82	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. <i>European Respiratory Journal</i> , 2013, 42, 252-271.	6.7	211
83	Prospects for Tuberculosis Elimination. <i>Annual Review of Public Health</i> , 2013, 34, 271-286.	17.4	312
84	Drug-resistant tuberculosis: latest advances. <i>Lancet Respiratory Medicine, the</i> , 2013, 1, e9-e10.	10.7	7
85	Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets. <i>The Lancet Global Health</i> , 2013, 1, e105-e115.	6.3	39
86	Tuberculosis. <i>New England Journal of Medicine</i> , 2013, 368, 745-755.	27.0	636
87	Linezolid for Extensively Drug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2013, 368, 290-291.	27.0	9
88	Drug-resistant tuberculosis: time for visionary political leadership. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 529-539.	9.1	243
89	Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 690-697.	9.1	72
90	Isoniazid preventive treatment: predictors of adverse events and treatment completion. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 903-908.	1.2	25

#	ARTICLE	IF	CITATIONS
91	Managing tuberculosis in people who use and inject illicit drugs. Bulletin of the World Health Organization, 2013, 91, 154-156.	3.3	20
92	Global Epidemiology of Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 003-016.	2.1	123
93	Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey. Antimicrobial Agents and Chemotherapy, 2013, 57, 2161-2166.	3.2	44
94	Setting new targets in the fight against tuberculosis. Nature Medicine, 2013, 19, 263-263.	30.7	27
95	Systematic screening for active tuberculosis: rationale, definitions and key considerations [State of the art series. Active case finding/screening. Number 1 in the series]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 289-298.	1.2	138
96	Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health Services. Journal of Infectious Diseases, 2012, 205, S216-S227.	4.0	98
97	Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bulletin of the World Health Organization, 2012, 90, 111-119D.	3.3	230
98	Tuberculosis and HIV in people who inject drugs. Current Opinion in HIV and AIDS, 2012, 7, 345-353.	3.8	34
99	Rational use of anti-tuberculosis drugs in the ELI: better patient care and less drug resistance. European Respiratory Journal, 2012, 39, 802-804.	6.7	11
100	Hurry up and wait? Accelerating access to the Three I's for HIV-TB [Editorial]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 853-854.	1.2	1
101	Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. European Respiratory Journal, 2012, 39, 1290-1291.	6.7	22
102	WHO's relationship with the Stop TB Partnership. Lancet, The, 2012, 379, 611-612.	13.7	1
103	A sustainable agenda for tuberculosis control and research. Lancet, The, 2012, 379, 1077-1078.	13.7	21
104	Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet, The, 2012, 379, 1902-1913.	13.7	300
105	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	6.7	188
106	Implementing the Global Plan to Stop TB, 2011-2015 - Optimizing Allocations and the Global Fund's Contribution: A Scenario Projections Study. PLoS ONE, 2012, 7, e38816.	2.5	17
107	Global tuberculosis control: lessons learnt and future prospects. Nature Reviews Microbiology, 2012, 10, 407-416.	28.6	199
108	Drug-Resistant Tuberculosis - Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. Journal of Infectious Diseases, 2012, 205, S228-S240.	4.0	140

#	ARTICLE	IF	CITATIONS
109	New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future. <i>Journal of Infectious Diseases</i> , 2012, 205, S241-S249.	4.0	159
110	Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2012, 18, e2-e2.	4.3	17
111	Hospital or home? Scripting a high point in the history of TB care and control. <i>WHO South-East Asia Journal of Public Health</i> , 2012, 1, 220.	0.7	3
112	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. <i>European Respiratory Journal</i> , 2011, 38, 516-528.	6.7	718
113	Tuberculosis: still a social disease [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 6-8.	1.2	35
114	Tuberculosis and poverty: what is being done [Counterpoint]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 431-432.	1.2	16
115	Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. <i>European Respiratory Journal</i> , 2011, 37, 1269-1282.	6.7	116
116	Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). <i>European Respiratory Journal</i> , 2011, 38, 493-495.	6.7	40
117	Preventing and managing antimicrobial resistance: imperative for chest physicians. <i>European Respiratory Journal</i> , 2011, 37, 978-981.	6.7	21
118	Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing. <i>Clinical Infectious Diseases</i> , 2011, 52, 901-906.	5.8	25
119	Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. <i>Bulletin of the World Health Organization</i> , 2011, 89, 573-582.	3.3	61
120	Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. <i>European Respiratory Journal</i> , 2011, 37, 950-959.	6.7	53
121	What Research Is Needed to Stop TB? Introducing the TB Research Movement. <i>PLoS Medicine</i> , 2011, 8, e1001135.	8.4	22
122	Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. <i>Bulletin of the World Health Organization</i> , 2011, 89, 616-618.	3.3	14
123	The WHO policy package to combat antimicrobial resistance. <i>Bulletin of the World Health Organization</i> , 2011, 89, 390-392.	3.3	227
124	Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. <i>Aids</i> , 2010, 24, S57-S65.	2.2	90
125	Tuberculosis is a global health issue: challenges and need for new tools. <i>BMC Proceedings</i> , 2010, 4, .	1.6	3
126	Stopping tuberculosis in the 21st century: Goals and strategies. <i>Respirology</i> , 2010, 15, 32-43.	2.3	46



#	ARTICLE	IF	CITATIONS
127	The European Respiratory Journal targets tuberculosis. <i>European Respiratory Journal</i> , 2010, 36, 714-715.	6.7	5
128	MDR Tuberculosis " Critical Steps for Prevention and Control. <i>New England Journal of Medicine</i> , 2010, 363, 1050-1058.	27.0	168
129	Giving a voice to those who die young: the fatal impact of tuberculosis and HIV in South Africa. <i>Future Microbiology</i> , 2010, 5, 1641-1643.	2.0	0
130	New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.6	106
131	Prevention and control of tuberculosis during air travel. <i>Travel Medicine and Infectious Disease</i> , 2010, 8, 79-80.	3.0	0
132	Tuberculosis control and elimination 2010"50: cure, care, and social development. <i>Lancet, The</i> , 2010, 375, 1814-1829.	13.7	697
133	Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. <i>Lancet, The</i> , 2010, 375, 2179-2191.	13.7	114
134	Tuberculosis control is crucial to achieve the MDGs. <i>Lancet, The</i> , 2010, 376, 940-941.	13.7	18
135	Active case-finding for TB in the community: time to act. <i>Lancet, The</i> , 2010, 376, 1205-1206.	13.7	17
136	Here is diabetes in The Lancet's tuberculosis Series!. <i>Lancet, The</i> , 2010, 376, 1987-1988.	13.7	0
137	A Road Map to Control Malaria, Tuberculosis, and Human Immunodeficiency Virus/AIDS. <i>Archives of Internal Medicine</i> , 2009, 169, 1650.	3.8	4
138	Trends in tuberculosis incidence and their determinants in 134 countries. <i>Bulletin of the World Health Organization</i> , 2009, 87, 683-691.	3.3	282
139	Drivers of tuberculosis epidemics: The role of risk factors and social determinants. <i>Social Science and Medicine</i> , 2009, 68, 2240-2246.	3.8	775
140	The principles of primary health care and social justice. <i>Journal of Medicine and the Person</i> , 2009, 7, 103-105.	0.1	0
141	The Global Fight Against HIV/AIDS, Tuberculosis, and Malaria. <i>American Journal of Clinical Pathology</i> , 2009, 131, 844-848.	0.7	158
142	Global Burden and Epidemiology of Tuberculosis. <i>Clinics in Chest Medicine</i> , 2009, 30, 621-636.	2.1	85
143	The history of the DOTS strategy Achievements and perspectives. , 2009, , 930-939.		1
144	The WHO Stop TB Strategy for the coming decade. , 2009, , 940-948.		0

#	ARTICLE	IF	CITATIONS
145	Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. <i>Lancet, The</i> , 2009, 373, 1861-1873.	13.7	353
146	Global TB Control: Persisting Problem, Shifting Solutions. , 2009, , 243-255.		0
147	Tuberculosis and air travel: WHO guidance in the era of drug-resistant TB. <i>Travel Medicine and Infectious Disease</i> , 2008, 6, 177-181.	3.0	25
148	Limitations on Human Rights: Are They Justifiable to Reduce the Burden of TB in the Era of MDR- and XDR-TB?. <i>Health and Human Rights</i> , 2008, 10, 121.	1.3	12
149	Global Epidemiology of Tuberculosis: Prospects for Control. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 481-491.	2.1	240
150	Facing Extensively Drug-Resistant Tuberculosis - A Hope and a Challenge. <i>New England Journal of Medicine</i> , 2008, 359, 636-638.	27.0	32
151	From Threat to Reality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 216-217.	5.6	5
152	Clinical and operational value of the extensively drug-resistant tuberculosis definition. <i>European Respiratory Journal</i> , 2007, 30, 623-626.	6.7	179
153	Patients with Previously Treated Tuberculosis No Longer Neglected. <i>Clinical Infectious Diseases</i> , 2007, 44, 61-64.	5.8	36
154	Controlling multidrug-resistant tuberculosis in India - Authors' reply. <i>Lancet, The</i> , 2007, 369, 742.	13.7	1
155	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 857-871.	4.4	101
156	XDR Tuberculosis - Implications for Global Public Health. <i>New England Journal of Medicine</i> , 2007, 356, 656-659.	27.0	341
157	125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. <i>European Respiratory Journal</i> , 2007, 29, 423-427.	6.7	166
158	Extensively Drug-resistant Tuberculosis, Italy and Germany. <i>Emerging Infectious Diseases</i> , 2007, 13, 780-782.	4.3	96
159	Planning to improve global health: the next decade of tuberculosis control. <i>Bulletin of the World Health Organization</i> , 2007, 85, 341-347.	3.3	59
160	The new Stop TB Strategy and the Global Plan to Stop TB 2006-2015. <i>Bulletin of the World Health Organization</i> , 2007, 85, 327-327.	3.3	52
161	The "vertical-horizontal" debates: time for the pendulum to rest (in peace)?. <i>Bulletin of the World Health Organization</i> , 2007, 85, 413-414.	3.3	32
162	Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. <i>Lancet Infectious Diseases, The</i> , 2006, 6, 483-495.	9.1	132

#	ARTICLE	IF	CITATIONS
163	International Standards for Tuberculosis Care. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 710-725.	9.1	308
164	WHO's new Stop TB Strategy. <i>Lancet</i> , The, 2006, 367, 952-955.	13.7	340
165	Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug) <i>Tj ETQq1 1 0.784314</i> <i>Overlock 10</i> <i>13.7</i> <i>294</i>	13.7	294
166	Multidrug-resistant Tuberculosis Management in Resource-limited Settings. <i>Emerging Infectious Diseases</i> , 2006, 12, 1389-1397.	4.3	152
167	Improving the TB case management: the International Standards for Tuberculosis care. <i>European Respiratory Journal</i> , 2006, 28, 687-690.	6.7	44
168	Tuberculosis care and control. <i>Bulletin of the World Health Organization</i> , 2006, 84, 428-428.	3.3	4
169	The Global Plan to Stop TB, 2006-2015. <i>International Journal of Tuberculosis and Lung Disease</i> , 2006, 10, 238-9.	1.2	26
170	XDR-TB: entering the post-antibiotic era?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2006, 10, 1185-7.	1.2	68
171	Tuberculosis control in the era of HIV. <i>Nature Reviews Immunology</i> , 2005, 5, 819-826.	22.7	216
172	The health workforce crisis in TB control: a report from high-burden countries. <i>Human Resources for Health</i> , 2005, 3, 2.	3.1	46
173	Global Epidemiology of Tuberculosis. <i>Clinics in Chest Medicine</i> , 2005, 26, 167-182.	2.1	127
174	Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2767.	7.4	398
175	Monitoring global health. <i>BMJ: British Medical Journal</i> , 2005, 330, 195.2.	2.3	4
176	Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. <i>European Respiratory Journal</i> , 2004, 24, 11-17.	6.7	53
177	Global Epidemiology of Tuberculosis. , 2004, , 33-43.		0
178	Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. <i>Lancet</i> , The, 2004, 363, 320-324.	13.7	25
179	Scale up: meeting targets in global tuberculosis control. <i>Lancet</i> , The, 2004, 363, 814-819.	13.7	75
180	Tuberculosis as a Major Global Health Problem in the 21st Century: A WHO Perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 245-253.	2.1	29

#	ARTICLE	IF	CITATIONS
181	The TB epidemic from 1992 to 2002. <i>Tuberculosis</i> , 2003, 83, 4-14.	1.9	221
182	The Growing Burden of Tuberculosis. <i>Archives of Internal Medicine</i> , 2003, 163, 1009.	3.8	2,147
183	European framework for tuberculosis control and elimination in countries with a low incidence. <i>European Respiratory Journal</i> , 2002, 19, 765-775.	6.7	268
184	Resources Required for Global Tuberculosis Control. <i>Science</i> , 2002, 295, 2040-2041.	12.6	46
185	Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis. <i>Science</i> , 2002, 295, 2042-2046.	12.6	289
186	Evolution of WHO policies for tuberculosis control, 1948â€“2001. <i>Lancet, The</i> , 2002, 359, 775-780.	13.7	181
187	Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. <i>Lancet, The</i> , 2002, 359, 1980-1989.	13.7	185
188	The global tuberculosis situation: Progress and problems in the 20th century, prospects for the 21st century. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 1-58.	5.1	86
189	Increasing transparency in partnerships for health - introducing the Green Light Committee. <i>Tropical Medicine and International Health</i> , 2002, 7, 970-976.	2.3	100
190	How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. <i>Bulletin of the World Health Organization</i> , 2002, 80, 939-45.	3.3	33
191	Rebuttal: Evidence and uncertainties. <i>International Journal of Tuberculosis and Lung Disease</i> , 2002, 6, 651-3.	1.2	2
192	Private practitioners and public health: weak links in tuberculosis control. <i>Lancet, The</i> , 2001, 358, 912-916.	13.7	204
193	Global Trends in Resistance to Antituberculosis Drugs. <i>New England Journal of Medicine</i> , 2001, 344, 1294-1303.	27.0	567
194	Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. <i>European Respiratory Journal</i> , 2001, 18, 369-375.	6.7	12
195	The Burden of Drug-Resistant Tuberculosis and Mechanisms for Its Control. <i>Annals of the New York Academy of Sciences</i> , 2001, 953b, 88-97.	3.8	59
196	PUBLIC HEALTH: Responding to Market Failures in Tuberculosis Control. <i>Science</i> , 2001, 293, 1049-1051.	12.6	120
197	Issues Facing TB Control (7) Multiple Drug-Resistant Tuberculosis. <i>Scottish Medical Journal</i> , 2000, 45, 52-55.	1.3	15
198	Supervised Preventive Therapy for Latent Tuberculosis Infection in Illegal Immigrants in Italy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1653-1655.	5.6	35

#	ARTICLE	IF	CITATIONS
199	Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis. JAMA - Journal of the American Medical Association, 2000, 283, 2537.	7.4	417
200	DOTS and multidrug-resistant tuberculosis. Resurgent and Emerging Infectious Diseases, 2000, , 115-131.	0.2	1
201	Global Burden of Tuberculosis. JAMA - Journal of the American Medical Association, 1999, 282, 677.	7.4	2,526
202	An African solution?. Lancet, The, 1999, 353, 1530.	13.7	1
203	Prospective multicentre study on the evaluation of antituberculosis treatment results in Italy: comparison of the culture- versus the smear-based methods. European Respiratory Journal, 1999, 13, 900.	6.7	7
204	Global Surveillance for Antituberculosis-Drug Resistance, 1994-1997. New England Journal of Medicine, 1998, 338, 1641-1649.	27.0	713
205	Epidemiology of Tuberculosis in the World. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 419-429.	2.1	28
206	Drug-Resistant Tuberculosis: Review of the Worldwide Situation and the WHO/IUATLD Global Surveillance Project. Clinical Infectious Diseases, 1997, 24, S121-S130.	5.8	279
207	Assessment of worldwide tuberculosis control. Lancet, The, 1997, 350, 624-629.	13.7	172
208	Costs and benefits of improving tuberculosis control: The case of Thailand. Social Science and Medicine, 1997, 44, 1805-1816.	3.8	26
209	Epidemiology, Control and Treatment of Multidrug-Resistant Tuberculosis. Drugs, 1996, 52, 103-108.	10.9	12
210	Surveillance of tuberculosis in Europe. European Respiratory Journal, 1996, 9, 1097-1104.	6.7	111
211	Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. Aids, 1995, 9, 267-274.	2.2	66
212	Validation of the surveillance system for new cases of tuberculosis in a province of Northern Italy. European Respiratory Journal, 1995, 8, 1252-1258.	6.7	21
213	Global Epidemiology of Tuberculosis. JAMA - Journal of the American Medical Association, 1995, 273, 220.	7.4	750
214	Tuberculosis trends in Eastern Europe and the former USSR. Tubercle and Lung Disease, 1994, 75, 400-416.	2.1	88
215	Tuberculosis and HIV infection. Lancet, The, 1993, 342, 1368-1369.	13.7	1
216	Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1. Archives of Disease in Childhood, 1993, 68, 665-668.	1.9	78

#	ARTICLE	IF	CITATIONS
217	Risk of Exposure to HIV-Infected Body Fluids Among Medical Housestaff. <i>AIDS Patient Care and STDs</i> , 1992, 6, 52-55.	0.1	2
218	A Pilot Study. <i>AIDS Patient Care and STDs</i> , 1991, 5, 120-124.	0.1	0
219	Extrapulmonary pneumocytosis in AIDS. <i>Infectious Diseases Newsletter (New York, NY)</i> , 1991, 10, 53-55.	0.4	0
220	<i>S. aureus</i> nasal carriage among homosexual men with and without HIV infection. <i>American Journal of Infection Control</i> , 1991, 19, 98-100.	2.3	15
221	Pleural <i>Pneumocystis carinii</i> Infection*. <i>Chest</i> , 1991, 99, 774-776.	0.8	14
222	<i>Pneumocystis Carinii</i> Infection of the Thyroid in a Hypothyroid Patient with AIDS: Diagnosis by Fine Needle Aspiration Biopsy*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 724-726.	3.6	36
223	Drug-resistant Tuberculosis in AIDS. <i>Chest</i> , 1990, 97, 511-512.	0.8	5
224	Ciprofloxacin-resistant methicillin-resistant <i>Staphylococcus aureus</i> in an acute-care hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 2050-2054.	3.2	96
225	Extrapulmonary <i>Pneumocystosis</i> : The First 50 Cases. <i>Clinical Infectious Diseases</i> , 1990, 12, 1127-1138.	5.8	143
226	Clinical Features and Management of Severe Dermatological Reactions to Drugs. <i>Drug Safety</i> , 1990, 5, 39-64.	3.2	22
227	Group G streptococcal meningitis and sepsis in a patient with AIDS a method to biotype group G streptococcus. <i>Diagnostic Microbiology and Infectious Disease</i> , 1990, 13, 261-264.	1.8	10
228	High <i>Staphylococcus aureus</i> nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. <i>American Journal of Infection Control</i> , 1990, 18, 64-69.	2.3	60
229	Extrapulmonary <i>Pneumocystis</i> Infection. <i>Annals of Internal Medicine</i> , 1989, 111, 339.	3.9	29
230	Cardiopulmonary Resuscitation in Patients With Acquired Immunodeficiency Syndrome-Reply. <i>Archives of Internal Medicine</i> , 1989, 149, 2380.	3.8	0
231	Splenectomy in patients with AIDS. <i>American Journal of Hematology</i> , 1989, 32, 184-189.	4.1	26
232	Infections associated with hickman catheters in patients with acquired immunodeficiency syndrome. <i>American Journal of Medicine</i> , 1989, 86, 780-786.	1.5	132
233	Fatal Toxic Epidermal Necrolysis During Prophylaxis With Pyrimethamine and Sulfadoxine in a Human Immunodeficiency Virus-Infected Person. <i>Archives of Internal Medicine</i> , 1988, 148, 2683.	3.8	30
234	Cardiopulmonary Resuscitation in Patients With the Acquired Immunodeficiency Syndrome. <i>Archives of Internal Medicine</i> , 1988, 148, 2602.	3.8	13

#	ARTICLE	IF	CITATIONS
235	Precision global health: a roadmap for augmented action. Journal of Public Health and Emergency, 0, 4, 5-5.	4.4	5
236	Molecular Evidence for SARS-CoV-2 in Samples Collected From Patients With Morbilliform Eruptions Since Late Summer 2019 in Lombardy, Northern Italy. SSRN Electronic Journal, 0, , .	0.4	8
237	Evolution of the strategies for control and elimination of tuberculosis. , 0, , 36-61.		3